UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

Clinical cancer research, 2005-02, Vol.11 (4), p.1504-1511

2005

Volltextzugriff (PDF)

Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes

JNCI : Journal of the National Cancer Institute, 2004-11, Vol.96 (21), p.1585-1592

2004

Volltextzugriff (PDF)

Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib

Journal of clinical oncology, 2006-06, Vol.24 (18), p.e30-e31

2006

Volltextzugriff (PDF)

Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel

The oncologist (Dayton, Ohio), 2007-03, Vol.12 (3), p.291-300

2007

Volltextzugriff (PDF)

Prophylaxis of Irinotecan‐Induced Diarrhea with Neomycin and Potential Role for UGT1A128 Genotype Screening: A Double‐Blind, Randomized, Placebo‐Controlled Study

The oncologist (Dayton, Ohio), 2006-09, Vol.11 (8), p.944-954

2006

Volltextzugriff (PDF)

Lifestyle habits as a contributor to anti-cancer treatment failure

European journal of cancer (1990), 2008-02, Vol.44 (3), p.374-382

2008

Volltextzugriff (PDF)

Effects of Mannose‐Binding Lectin Polymorphisms on Irinotecan‐Induced Febrile Neutropenia

The oncologist (Dayton, Ohio), 2010-10, Vol.15 (10), p.1063-1072

2010

Volltextzugriff (PDF)

Flat-fixed dosing of irinotecan: Influence on pharmacokinetic and pharmacodynamic variability

Clinical cancer research, 2004-06, Vol.10 (12), p.4068-4071

2004

Volltextzugriff (PDF)

Medicinal cannabis in oncology

European journal of cancer (1990), 2007-12, Vol.43 (18), p.2638-2644

2007

Volltextzugriff (PDF)

Effects of methimazole on the elimination of irinotecan

Cancer chemotherapy and pharmacology, 2011-01, Vol.67 (1), p.231-236

2011

Volltextzugriff (PDF)

CORRECT-MRD I: A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD)

Journal of clinical oncology, 2024-08, Vol.42 (23_suppl), p.TPS98-TPS98

2024

Volltextzugriff (PDF)

Safety and Efficacy of Tinostamustine in Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL): Early Results from an Additional Expansion Cohort of a Phase I Study

Blood, 2022-11, Vol.140 (Supplement 1), p.3696-3697

2022

Volltextzugriff (PDF)

Medicinal cannabis in oncology practice: still a bridge too far?

Journal of clinical oncology, 2005-05, Vol.23 (13), p.2886-2891

2005

Volltextzugriff (PDF)

Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2003-10, Vol.795 (2), p.383-388

2003

Volltextzugriff (PDF)

Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.459-459

2018

Volltextzugriff (PDF)

Dose modifications of liposomal irinotecan (nal-IRI) + 5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.388-388

2018

Volltextzugriff (PDF)

Role of imatinib mesylate (Gleevec®/Glivec®) in gastrointestinal stromal tumors

Expert review of anticancer therapy, 2003-12, Vol.3 (6), p.757-766

2003

Volltextzugriff (PDF)

A phase 1/2, open-label dose-escalation study of liposomal irinotecan (nal-IRI) plus 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4111-4111

2018

Volltextzugriff (PDF)

Flat-Fixed Dosing of Irinotecan

Clinical cancer research, 2004-06, Vol.10 (12), p.4068-4071

2004

Volltextzugriff (PDF)

ABCG2 Pharmacogenetics

Clinical cancer research, 2004-09, Vol.10 (17), p.5889-5894

2004

Volltextzugriff (PDF)

Subgroup analysis by measurable metastatic lesion (ML) number and selected lesion locations (LL) at baseline (BL) in NAPOLI-1: A phase III study of liposomal irinotecan (nal-IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.460-460

2018

Volltextzugriff (PDF)

Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/ leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy

Journal of clinical oncology, 2018-02, Vol.36 (4_suppl), p.379-379

2018

Volltextzugriff (PDF)

Pharmacokinetics (PK) of panitumumab in a single patient with metastatic colorectal cancer (mCRC) and liver dysfunction

Journal of clinical oncology, 2013-02, Vol.31 (4_suppl), p.594-594

2013

Volltextzugriff (PDF)

The prognostic value of baseline neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398) + 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15795-e15795

2017

Volltextzugriff (PDF)

26 – 50 von 158

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(143)
Mit Volltextzugriff
(144)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(101)
Life Sciences & Biomedicine
(93)
Humans
(76)
Male
(43)
Oncology
(40)
Female
(38)
Middle Aged
(36)
Adult
(32)
Aged
(29)
Biological And Medical Sciences
(22)
Irinotecan
(21)
Medical Sciences
(21)
Camptothecin - Analogs & Derivatives
(19)
Patients
(16)
Tumors
(16)
Camptothecin - Pharmacokinetics
(13)
Pharmacology. Drug Treatments
(12)
Pharmacokinetics
(11)
Treatment Outcome
(11)
Antineoplastic Agents, Phytogenic - Pharmacokinetics
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Phase I Pharmacokinetic, Food Effect, and Pharmacogenetic Study of Oral Irinotecan Given as Semisolid Matrix Capsules in Patients with Solid Tumors

Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes

Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib

Medicinal Cannabis Does Not Influence the Clinical Pharmacokinetics of Irinotecan and Docetaxel

Prophylaxis of Irinotecan‐Induced Diarrhea with Neomycin and Potential Role for UGT1A128 Genotype Screening: A Double‐Blind, Randomized, Placebo‐Controlled Study

Lifestyle habits as a contributor to anti-cancer treatment failure

Effects of Mannose‐Binding Lectin Polymorphisms on Irinotecan‐Induced Febrile Neutropenia

Flat-fixed dosing of irinotecan: Influence on pharmacokinetic and pharmacodynamic variability

Medicinal cannabis in oncology

Effects of methimazole on the elimination of irinotecan

CORRECT-MRD I: A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD)

Safety and Efficacy of Tinostamustine in Pre-Treated Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL): Early Results from an Additional Expansion Cohort of a Phase I Study

Medicinal cannabis in oncology practice: still a bridge too far?

Determination of irinotecan (CPT-11) and SN-38 in human whole blood and red blood cells by liquid chromatography with fluorescence detection

Nomogram for predicting overall survival (OS) in patients (pts) treated with liposomal irinotecan (nal-IRI) ± 5-fluorouracil/leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy in NAPOLI-1

Dose modifications of liposomal irinotecan (nal-IRI) + 5-fluorouracil/leucovorin (5-FU/LV) in NAPOLI-1: Impact on efficacy

Role of imatinib mesylate (Gleevec®/Glivec®) in gastrointestinal stromal tumors

A phase 1/2, open-label dose-escalation study of liposomal irinotecan (nal-IRI) plus 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer (mPAC)

Flat-Fixed Dosing of Irinotecan

ABCG2 Pharmacogenetics

Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy

Pharmacokinetics (PK) of panitumumab in a single patient with metastatic colorectal cancer (mCRC) and liver dysfunction

Suchergebnisse filtern